text
"['\n4. 매출 및 수주상황\n가. 연결기준\xa0\n(단위: 백만원)\n구분\n2023년 1분기\n2022년\n2021년\n사업부문\n품목\n국내\n해외\n합계\n국내\n해외\n합계\n국내\n해외\n합계\n의약품 제조 및 판매\n혈액제제류\n79,927\n36,882\n116,809\n329,493\n136,636\n466,129\n312,885\n132,967\n445,852\nOTC류\n30,488\n34\n30,522\n141,953\n513\n142,466\n174,174\n237\n174,411\n일반제제류\n80,154\n11,356\n91,510\n325,556\n52,190\n377,746\n283,655\n32,546\n316,201\n백신제제\n15,380\n11,681\n27,061\n137,902\n118,518\n256,420\n155,939\n107,229\n263,168\n기타\n51,883\n4,183\n56,066\n259,590\n27,849\n287,439\n210,773\n37,062\n247,835\n검체 등 진단 및 분석\n47,675\n1,314\n48,989\n248,207\n16,167\n264,374\n187,367\n-\n187,367\n의료 서비스 및 시스템 개발공급\n44,315\n-\n44,315\n166,042\n-\n166,042\n141,569\n-\n141,569\n임대 및 서비스업\n27,139\n-\n27,139\n66,770\n-\n66,770\n73,934\n-\n73,934\n기타\n43,230\n3,622\n46,852\n191,561\n17,414\n208,975\n151,719\n4,332\n156,051\n보고부문 합계\n420,190\n69,072\n489,263\n1,867,074\n369,287\n2,236,361\n1,692,015\n314,373\n2,006,388\n연결조정 등\n-\n-\n(50,961)\n-\n-\n(156,801)\n-\n-\n(165,829)\n연결재무제표 금액\n-\n-\n438,302\n-\n-\n2,079,560\n-\n-\n1,840,559\n나. 별도기준\xa0\n(단위 : 백만원)\n\xa0 \xa0 \xa0 \xa0 \xa0구 \xa0분\n2023년 1분기\n2022년\n2021년\n영업수익:\n임대료수익\n3,090\n15,003\n14,712\n배당금수익\n18,401\n23,675\n32,779\n기타영업수익\n5,648\n28,092\n26,443\n합계\n27,139\n66,770\n73,934\n다. 수주상황\n(단위 : )\n품목\n수주일자\n납기\n수주총액\n기납품액\n수주잔고\n수량\n금액\n수량\n금액\n수량\n금액\n-\n-\n-\n-\n-\n-\n-\n-\n-\n합 계\n-\n-\n-\n-\n-\n-\n']"
